Nakayama Yuko, Nakagomi Hiroshi, Omori Masato, Inoue Masayuki, Takahashi Kazunori, Maruyama Masahiro, Takano Atsushi, Furuya Kazushige, Amemiya Kenji, Ishii Eri, Oyama Toshio
Department of Surgery, Yamanashi Prefectural Central Hospital, Fujimi1-1-1, Kofu, Yamanashi, Japan.
Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Breast Cancer. 2016 Jul;23(4):633-9. doi: 10.1007/s12282-015-0615-x. Epub 2015 May 13.
The discordance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressions between primary cancer and metastatic lesions is an important issue when selecting the optimal treatments for patients with metastatic breast cancer. A rebiopsy for the metastatic cancer is recommended before selecting the treatment; however, it is not easy to take a tissue sample for all metastatic lesions. Fine needle aspiration cytology (FNA) for regional lymph nodes and aspiration for pleural effusions or ascites are less invasive procedures to obtain the necessary samples to examine the HR/HER2 expression. These cytologic materials are able to be stained as a tissue sample using the cell block method.
We examined the HR/HER2 expression of 20 patients with breast cancer (8 with synchronous metastases and 12 with metachronous metastases) using the cell block method. Among 8 patients with synchronous metastases, 7 patients with axillary lymph node (LN) metastasis were examined by fine needle aspiration (FNA), and one patient with pleural metastases was analyzed for the aspirated fluid. While in 12 patients with metachronous metastases, 7 patients were examined for their pleural effusion, 3 patients were examined for regional lymph node metastases, and 1 patient were examined for aspirated ascites. We compared the HR/HER expression between primary cancer and metastatic lesion in 17 patients (5 cases of 8 synchronous metastases, and all of 12 metachronous metastases).
Discordance of HR was seen in 4 of 17 patients (24 %). Three cases with axillary LN metastasis (2 cases with synchronous metastases and one with metachronous metastasis) showed negative change of ER. Negative change of HER2 expression was seen in one patient with ascites caused by peritoneal dissemination.
Cytology materials are easily obtained by FNA for LN metastases and aspiration for malignant effusions and analyzed for HR/HER2 expression using cell block method. We should take advantage of cell block analysis to determine the discordance of the HR/HER2 expression to select the optimal treatment for metastatic breast cancer.
在为转移性乳腺癌患者选择最佳治疗方案时,原发癌与转移灶之间激素受体(HR)和人表皮生长因子受体2(HER2)表达的不一致是一个重要问题。建议在选择治疗方案前对转移癌进行再次活检;然而,对所有转移灶进行组织取样并不容易。对区域淋巴结进行细针穿刺细胞学检查(FNA)以及对胸腔积液或腹水进行抽吸是获取用于检测HR/HER2表达所需样本的侵入性较小的方法。这些细胞学材料能够使用细胞块法作为组织样本进行染色。
我们使用细胞块法检测了20例乳腺癌患者(8例为同时性转移,12例为异时性转移)的HR/HER2表达。在8例同时性转移患者中,7例腋窝淋巴结(LN)转移患者通过细针穿刺(FNA)进行检测,1例胸膜转移患者对抽吸液进行了分析。而在12例异时性转移患者中,7例对胸腔积液进行了检测,3例对区域淋巴结转移进行了检测,1例对抽吸腹水进行了检测。我们比较了17例患者(8例同时性转移中的5例,以及12例异时性转移中的全部患者)原发癌与转移灶之间的HR/HER表达。
17例患者中有4例(24%)出现HR不一致。3例腋窝LN转移患者(2例同时性转移和1例异时性转移)ER呈阴性变化。1例因腹膜播散导致腹水的患者HER2表达呈阴性变化。
通过FNA对LN转移灶以及对恶性积液进行抽吸可轻松获取细胞学材料,并使用细胞块法分析HR/HER2表达。我们应利用细胞块分析来确定HR/HER2表达的不一致情况,从而为转移性乳腺癌选择最佳治疗方案。